Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

6,016 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Contemporary analysis of the influence of acute kidney injury (AKI) after myeloablative hematopoietic cell transplantation on long-term patient's survival.
Lopes JA, Jorge S, Gonçalves S, Resina C, Silva S, de Almeida E, Abreu F, Lourenço F, Martins C, Lacerda JF, do Carmo JA, Prata MM. Lopes JA, et al. Among authors: silva s. Bone Marrow Transplant. 2008 Jul;42(2):139-41. doi: 10.1038/bmt.2008.97. Epub 2008 Apr 21. Bone Marrow Transplant. 2008. PMID: 18425145 No abstract available.
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial.
Heerspink HJL, Radhakrishnan J, Alpers CE, Barratt J, Bieler S, Diva U, Inrig J, Komers R, Mercer A, Noronha IL, Rheault MN, Rote W, Rovin B, Trachtman H, Trimarchi H, Wong MG, Perkovic V; PROTECT Investigators. Heerspink HJL, et al. Lancet. 2023 May 13;401(10388):1584-1594. doi: 10.1016/S0140-6736(23)00569-X. Epub 2023 Apr 1. Lancet. 2023. PMID: 37015244 Clinical Trial.
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.
Rovin BH, Barratt J, Heerspink HJL, Alpers CE, Bieler S, Chae DW, Diva UA, Floege J, Gesualdo L, Inrig JK, Kohan DE, Komers R, Kooienga LA, Lafayette R, Maes B, Małecki R, Mercer A, Noronha IL, Oh SW, Peh CA, Praga M, Preciado P, Radhakrishnan J, Rheault MN, Rote WE, Tang SCW, Tesar V, Trachtman H, Trimarchi H, Tumlin JA, Wong MG, Perkovic V; DUPRO steering committee and PROTECT Investigators. Rovin BH, et al. Lancet. 2023 Dec 2;402(10417):2077-2090. doi: 10.1016/S0140-6736(23)02302-4. Epub 2023 Nov 3. Lancet. 2023. PMID: 37931634 Clinical Trial.
Impact of long-stay beds on the performance of a tertiary hospital in emergencies.
Pazin-Filho A, de Almeida E, Cirilo LP, Lourençato FM, Baptista LM, Pintyá JP, Capeli RD, Silva SM, Wolf CM, Dinardi MM, Scarpelini S, Damasceno MC. Pazin-Filho A, et al. Among authors: silva sm. Rev Saude Publica. 2015;49:83. doi: 10.1590/S0034-8910.2015049006078. Epub 2015 Nov 24. Rev Saude Publica. 2015. PMID: 26603353 Free PMC article.
6,016 results